tiprankstipranks
Trending News
More News >

NeuroPace Announces Promising NAUTILUS Study Results

Story Highlights
  • NeuroPace announced preliminary results from the NAUTILUS study on May 27, 2025.
  • The study showed significant seizure reduction in a key patient subgroup, boosting confidence in NeuroPace’s growth strategy.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
NeuroPace Announces Promising NAUTILUS Study Results

Don’t Miss TipRanks’ Half-Year Sale

NeuroPace ( (NPCE) ) just unveiled an announcement.

On May 27, 2025, NeuroPace announced the preliminary one-year results of its NAUTILUS study, which evaluates the safety and effectiveness of the RNS System for treating drug-resistant idiopathic generalized epilepsy. The study met its primary safety endpoint and showed significant seizure reduction in a key patient subgroup, suggesting potential benefits for a substantial portion of patients. NeuroPace plans to engage with the FDA regarding regulatory pathways and is confident in its long-term growth strategy, reaffirming its 2025 financial guidance.

The most recent analyst rating on (NPCE) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on NeuroPace stock, see the NPCE Stock Forecast page.

Spark’s Take on NPCE Stock

According to Spark, TipRanks’ AI Analyst, NPCE is a Neutral.

NeuroPace’s stock score reflects a mix of promising growth potential and significant financial challenges. Strong revenue growth and technical momentum are key strengths, but the financial struggles and valuation concerns weigh heavily. The positive guidance and corporate events provide some confidence, but the need for improved financial health and operational efficiencies remains critical.

To see Spark’s full report on NPCE stock, click here.

More about NeuroPace

NeuroPace, based in Mountain View, Calif., is a medical device company focused on improving the lives of individuals with epilepsy through its innovative RNS System, a brain-responsive platform that provides personalized, real-time treatment for drug-resistant epilepsy.

Average Trading Volume: 246,687

Technical Sentiment Signal: Buy

Current Market Cap: $579.9M

For detailed information about NPCE stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1